investorscraft@gmail.com

Intrinsic value of Exact Sciences Corporation (EXAS)

Previous Close$39.25
Intrinsic Value
Upside potential
Previous Close
$39.25

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh7.32 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-03-31.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %18.5NaN
Revenue, $1767NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m2623NaN
Operating income, $m-856NaN
EBITDA, $m-650NaN
Interest expense (income), $mNaN
Earnings before tax, $m-843NaN
Tax expense, $m-247NaN
Net income, $m-596NaN

BALANCE SHEET

Cash and short-term investments, $m1030NaN
Total assets, $m7177NaN
Adjusted assets (=assets-cash), $m6147NaN
Average production assets, $m3943NaN
Working capital, $m909NaN
Total debt, $m2401NaN
Total liabilities, $m3789NaN
Total equity, $m3388NaN
Debt-to-equity ratio0.709NaN
Adjusted equity ratio0.388NaN

CASH FLOW

Net income, $m-596NaN
Depreciation, amort., depletion, $m206NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m-86NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-194NaN
Free cash flow, $m108NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m909
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount